新辅助同步化免疫放疗后手术及辅助免疫治疗用于可切除非小细胞肺癌IIIA-B期N2患者:SQUAT试验(WJOG 12119L)主要结果
SQUAT试验(WJOG 12119L)是一项在10家日本机构开展的研究,纳入31例病理确诊无结外侵犯的临床T1-T3或T4(肿瘤大小)N2期IIIA-B期NSCLC患者,接受同步化放疗(卡铂AUC=2、紫杉醇40 mg/m2第1、8、15、22、29天,50 Gy放疗25天)联合度伐利尤单抗1500 mg第1、29天,2-6周后手术,术后度伐利尤单抗辅助治疗至多1年。主要终点主要病理缓解(MPR)率为63%(90%CI 47%-78%),达到主要终点;病理完全缓解率23%,中位随访28个月时2年PFS率43%、OS率76%,3-4级不良事件发生率48%,包括1例治疗相关死亡。作者认为该方案MPR率高于近期围手术期化免疫治疗试验,但该获益未必转化为PFS或OS改善。
要点
- 主要病理缓解(MPR)率63%(90%CI 47%-78%),达到主要终点;病理完全缓解率23%。
- 中位随访28个月时,2年无进展生存率43%、总生存率76%。
- 3-4级不良事件发生率48%,包括1例治疗相关死亡。
核心结论
- 与近期发表的围手术期化免疫治疗试验结果相比,该治疗方案主要病理缓解率更高,但该获益未必转化为无进展生存或总生存改善。
研究设计与样本
- 研究纳入31例病理确诊为N2且无结外侵犯的临床T1-T3或T4(肿瘤大小)N2期IIIA-B期NSCLC患者(美国癌症联合委员会第8版),来自10家日本机构。
- 患者接受同步化放疗(卡铂曲线下面积=2、紫杉醇40 mg/m2于第1、8、15、22、29天给药,50 Gy放疗25天)联合度伐利尤单抗1500 mg于第1、29天给药,2-6周后行手术切除。
- 术后度伐利尤单抗辅助治疗至多1年;主要终点为主要病理缓解(MPR:存活肿瘤≤10%),次要终点为病理完全缓解、无进展生存、总生存和安全性。
主要发现
- 2020年1月至2022年2月共入组31例患者,主要病理缓解率为63%(90%置信区间47%-78%),达到主要终点,病理完全缓解率为23%。
- 中位随访28个月时,2年无进展生存率和总生存率分别为43%和76%。
- 3级或4级不良事件发生率为48%,包括1例治疗相关死亡。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Neoadjuvant chemo-immunotherapy is one of the standard treatment options for resectable stage II to III NSCLC. Nevertheless, this treatment yielded insufficient local control in the CheckMate 816 trial. We hypothesized that adding radiotherapy could improve local control, thereby improving survival outcomes. METHODS: Eligible patients had clinical T1 to T3 or T4 (tumor size) N2 stage IIIA to B NSCLC (American Joint Committee on Cancer version 8), pathologically confirmed as N2 without extranodal invasion. Patients received concurrent chemoradiotherapy (carboplatin [area under the curve = 2] and paclitaxel [40 mg/m2] on days 1, 8, 15, 22, and 29, with 50 Gy radiation over 25 d) and durvalumab (1500 mg) on days 1 and 29, followed by surgical resection within two to six weeks. After surgery, durvalumab adjuvant therapy was administered for up to one year. The primary endpoint was major pathologic response (MPR: ≤10% viable tumor), with secondary endpoints being pathologic complete response, progression-free survival (PFS), overall survival (OS), and safety. RESULTS: From January 2020 through February 2022, 31 patients were enrolled from 10 Japanese institutions. The MPR rate was 63% (90% confidence interval: 47%-78%), which met the primary endpoint, and the pathologic complete response rate was 23%. At a median follow-up of 28 months, the two-year PFS and OS rates were 43% and 76%, respectively. Grade 3 or 4 adverse events occurred in 48% of cases, including one treatment-related death. CONCLUSIONS: Compared with recently published results of peri-operative chemo-immunotherapy trials, this treatment regimen had a higher MPR rate. Nevertheless, this benefit did not necessarily translate into improved PFS or OS.
引用
- Hamada A, Soh J, Hata A, et al. Neoadjuvant Concurrent Chemo-Immuno-Radiation Therapy Followed by Surgery and Adjuvant Immunotherapy for Resectable Stage III N2 NSCLC: Primary Results From the SQUAT Trial (WJOG 12119L). J Thorac Oncol. 2025. PMID: 40216327. doi:10.1016/j.jtho.2025.03.051
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。